Metastatic Breast Cancer-Specific Prognostic Tool

Sponsor
UNC Lineberger Comprehensive Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05574478
Collaborator
(none)
30
1
24.4
1.2

Study Details

Study Description

Brief Summary

In this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interviews will be conducted by the UNC CHAI Core and will continue until thematic saturation (estimated 20-30 participants). The investigators will code the qualitative data using emerging themes, guided by a well-established implementation science theory, the Consolidated Framework for Implementation Research (CFIR). The information gained from these studies will inform an implementation approach to increase the usability and acceptability of a novel prognostic tool to assist oncologists in the prognosis of patients with metastatic breast cancer.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Patients and Caregivers Qualitative Interview

Detailed Description

If this study is successful, Investigators will implement an MBC-specific prognostic tool to help clinicians identify patients who are at high risk of death in the next 30 days. Based on the input from clinicians in this proposal, as well as additional qualitative studies with patients and families, Investigators will design an implementation protocol to inform how to use this tool in clinical practice. Rather than simply publishing a prognostic tool that may not be adopted into practice, this project aims to ensure successful implementation of an evidence-based tool into the routine care of patients with MBC. Doing so will serve as an important step towards identifying high-risk patients and connecting ort to ensure high-quality, patient-centered end-of-life care.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Ecologic or Community
Time Perspective:
Prospective
Official Title:
Evaluation of the Acceptability, Appropriateness, Feasibility and Utility of a Metastatic Breast Cancer-Specific Prognostic Tool Among Patients With Metastatic Breast Cancer and Their Caregivers
Actual Study Start Date :
Sep 20, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients and Caregivers

Participants will include patients diagnosed with metastatic breast cancer and caregivers for patients diagnosed with metastatic breast cancer. Participants will be recruited from the UNC Medical Center breast oncology group as well as other practices identified by the Principal Investigator based on existing professional networks (referring physicians, other UNC oncology entities, collaborative groups).

Behavioral: Patients and Caregivers Qualitative Interview
Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications & Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.

Outcome Measures

Primary Outcome Measures

  1. Determining the key patient and caregiver factors impacting implementation of a metastatic breast cancer prognostic tool through semi-structured qualitative interviews. [12 months]

    Study Investigators have developed a metastatic breast cancer (MBC)-specific prognostic calculator using the ASCO CancerLinQ Discovery database to help oncologists better estimate prognosis in MBC patients. Key factors impacting implementation of a MBC prognostic tool will be evaluated through semi-structured qualitative interviews with patients and caregivers.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. In order to participate in this study a subject must meet ALL of the eligibility criteria outlined below.

  2. Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.

  3. Diagnosis of metastatic breast cancer or primary caregiver for someone with a diagnosis of metastatic breast cancer

  4. Age > 18 years

  5. Verbal informed consent obtained to participate in the study.

  6. Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.

Exclusion Criteria:
  1. Non-English speaking

Contacts and Locations

Locations

Site City State Country Postal Code
1 Terri Eubanks Chapel Hill North Carolina United States 27599

Sponsors and Collaborators

  • UNC Lineberger Comprehensive Cancer Center

Investigators

  • Principal Investigator: Emily Ray, MD, University of North Carolina

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT05574478
Other Study ID Numbers:
  • LCCC2213
First Posted:
Oct 10, 2022
Last Update Posted:
Oct 10, 2022
Last Verified:
Oct 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by UNC Lineberger Comprehensive Cancer Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2022